Skip to main content

Table 1 Participant disposition

From: Randomized, placebo-controlled, double-blind trial of Swedish snus for smoking reduction and cessation

  319 Randomized
Baseline: 158 (100%) Assigned to snus 161 (100%) Assigned to placebo
  158 (100%) Received assigned product, included in efficacy and safety analyses 161 (100%) Received assigned product, included in efficacy and safety analyses
Week 1-24: 26 (16%) Discontinued study 23 (14%) Discontinued study
  132 (84%) Completed protocol follow-up 138 (86%) Completed protocol follow-up
Week 24 visit: 31 (20%) Failed to achieve protocol definition of smoking reduction 29 (18%) Failed to achieve protocol definition of smoking reduction
  101 (64%) Continued in the study 109 (68%) Continued in the study
Week 24-48: 13 (8%) Discontinued study 8 (5%) Discontinued study
  88 (56%) Completed protocol follow-up 101 (63%) Completed protocol follow-up